Taysha Gene Therapies (NASDAQ:TSHA – Get Rating) had its target price cut by equities researchers at JMP Securities from $20.00 to $6.00 in a report released on Thursday, The Fly reports. The firm presently has a “market outperform” rating on the stock. JMP Securities’ price target suggests a potential upside of 209.28% from the stock’s current price.
TSHA has been the topic of several other reports. Needham & Company LLC cut their target price on Taysha Gene Therapies from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Tuesday, November 8th. The Goldman Sachs Group downgraded Taysha Gene Therapies from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 9th. Canaccord Genuity Group assumed coverage on Taysha Gene Therapies in a research report on Tuesday, November 8th. They set a “buy” rating and a $16.00 price target on the stock. BTIG Research cut their price target on Taysha Gene Therapies from $25.00 to $15.00 in a research report on Thursday, November 10th. Finally, Guggenheim cut their price target on Taysha Gene Therapies from $22.00 to $19.00 in a research report on Tuesday, November 8th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $15.08.
Taysha Gene Therapies Price Performance
NASDAQ TSHA opened at $1.94 on Thursday. The company has a debt-to-equity ratio of 3.40, a current ratio of 1.30 and a quick ratio of 1.30. The stock’s fifty day moving average price is $2.18 and its 200 day moving average price is $2.76. Taysha Gene Therapies has a 1 year low of $1.35 and a 1 year high of $8.93. The company has a market cap of $121.14 million, a price-to-earnings ratio of -0.47 and a beta of 1.29.
Insider Activity at Taysha Gene Therapies
In other Taysha Gene Therapies news, Director Paul B. Manning purchased 1,500,000 shares of the company’s stock in a transaction on Monday, October 31st. The stock was acquired at an average price of $2.00 per share, for a total transaction of $3,000,000.00. Following the completion of the purchase, the director now directly owns 1,642,202 shares in the company, valued at approximately $3,284,404. The purchase was disclosed in a filing with the SEC, which is available through this link. 42.40% of the stock is owned by insiders.
Hedge Funds Weigh In On Taysha Gene Therapies
A number of institutional investors and hedge funds have recently modified their holdings of TSHA. Kovitz Investment Group Partners LLC acquired a new stake in Taysha Gene Therapies in the fourth quarter valued at $34,000. AQR Capital Management LLC acquired a new stake in shares of Taysha Gene Therapies during the second quarter worth about $38,000. Sargent Investment Group LLC increased its position in Taysha Gene Therapies by 41.9% in the 3rd quarter. Sargent Investment Group LLC now owns 25,242 shares of the company’s stock valued at $47,000 after acquiring an additional 7,454 shares during the period. Occudo Quantitative Strategies LP increased its position in Taysha Gene Therapies by 17.9% in the 2nd quarter. Occudo Quantitative Strategies LP now owns 31,030 shares of the company’s stock valued at $115,000 after acquiring an additional 4,702 shares during the period. Finally, Thompson Siegel & Walmsley LLC increased its position in Taysha Gene Therapies by 33.3% in the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 56,100 shares of the company’s stock valued at $209,000 after acquiring an additional 14,000 shares during the period. Institutional investors and hedge funds own 45.12% of the company’s stock.
Taysha Gene Therapies Company Profile
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
- Get a free copy of the StockNews.com research report on Taysha Gene Therapies (TSHA)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.